Tay-Sachs Disease Treatment Market size was over USD 2.29 billion in 2023 and is anticipated to reach USD 4.71 billion by 2036, witnessing around 5.7% CAGR during the forecast period i.e., between 2024-2036. In the year 2024, the industry size of tay-sachs disease treatment is estimated at USD 2.39 billion.
The growth of the market can be attributed to the growing prevalence of the genetic disease, especially among infants. Tay-Sachs disease is caused by the mutation in HEXA genes, which results into loss of control over muscles. There is no known cure for this disease, therefore, the treatment is generally symptom-specific. Symptoms include exaggerated reactions to loud noises, seizures, loss of movement, vision, and hearing, accumulation of mucus in lungs, and others. The genetic mutation is witnessed specifically in a few communities, such as, eastern and central European Jewish communities, Ashkenazi Jews, certain French-Canadian communities, old order Amish community, and Cajun community, among others. According to the data by the U.S. National Library of Medicine, in this specific Jewish population, one out of every 27 members carry this gene, and one out of every 250-300 live births is affected by Tay- Sachs disease. Rising population of these high-risk communities, is anticipated to boost the market growth. Moreover, increasing investment in R&D activities, to develop new treatment methods to cure the genetic disorder, along with the emergence of new and better drugs used to treat symptoms and complications associated with the disease, are estimated to boost he tay-sachs disease treatment market growth.
Growth Drivers
Challenges
|
2023 |
|
|
Forecast Year |
2024–2036 |
|
CAGR |
5.7% |
|
Base Year Market Size (2023) |
USD 2.29 billion |
|
Forecast Year Market Size (2036) |
USD 4.71 billion |
|
Regional Scope |
|
The tay-sachs disease treatment market is segmented by stage into infantile, juvenile, and late-onset, out of which, the infantile segment is anticipated to gain the largest revenue in the market during the forecast period, as the symptoms are very severe in infantile Tay-Sachs disease, and require immediate and constant treatment. The symptoms appear at 6-months of age, and include vision loss, movement loss, patches inside eyes, and respiratory issues. On the basis of end-user, the market is segmented into hospitals, homecare, specialty clinics, and others, out of which, the specialty clinics segment is projected to witness major growth during the forecast period, owing to the symptom specific, and targeted treatment provided in such clinics.
Our in-depth analysis of the global market includes the following segments:
|
Stage |
|
|
Treatment Type |
|
|
End-User |
|
Regionally, the tay-sachs disease treatment market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region. The market in North America is likely to hold largest revenue share by 2036, on the back of growing cases of Tay-Sachs disease in the region, backed by the high population of Amish, Cajun, and French-Canadian communities, in Pennsylvania, Louisiana, and Quebec, respectively. Moreover, the advanced healthcare system, along with growing R&D activities in the region, is estimated to boost the market growth. According to the data by the World Health Organization (WHO), as of 2018, 16.416 % of the GDP was spent on the healthcare sector in North America. The tay-sachs disease treatment market in the Middle East and Africa region is also estimated to witness moderate growth over the forecast period, owing to the high Jewish population in Israel, other neighboring countries.
There is no known cure for Tay-Sachs disease, but treatment is given for the symptoms, which can be different for different patients, and stages. The treatment approach can range from physical therapy, chest physiotherapy, and respiratory care, to antipsychotic medications, and other treatment methods. The major tay-sachs disease treatment market players manufacturing the various kind of drugs needed to treat the symptoms include
· September 9, 2020: Bayer AG to collaborate with Recursion Pharmaceuticals, Inc., to step into research and drug discovery.
Author Credits: Radhika Pawar
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?